Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1394-1395

  Lam, Marnix G E H ^a   Zonnenberg, Bernard A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153;

BONE METASTASIS; CANCER HORMONE THERAPY; DRUG EFFICACY; HUMAN; LETTER; MULTIMODALITY CANCER THERAPY; PAIN ASSESSMENT; PROSTATE CANCER; VISUAL ANALOG SCALE;

EID: 45049083000     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0782-5     Document Type: Letter

References (6)

1. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21:2869-75.
2. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-41.
3. Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging. 2008;35:756-5.
4. Han SH, de Klerk JM, Tan S, het Schip AD, Derksen BH, van Dijk A, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med. 2002;43:1150-6.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
6. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008; 34:103-21